Clearmind Medicine Inc. has successfully completed patient enrollment for Part C of its CMND-100 Phase I/IIa clinical trial. This marks a significant milestone in the company's efforts to develop non-hallucinogenic treatments for neuropsychiatric disorders, including alcohol use disorder (AUD).
The completion of patient enrollment for Part C demonstrates Clearmind's continued progress in its clinical development program. This achievement follows the successful enrollment of the first cohort in Part B, which evaluated CMND-100 in patients with moderate-to-severe AUD. It builds on the encouraging safety and tolerability data obtained from Part A, which involved healthy volunteers.
Background
Clearmind Medicine Inc. is a clinical-stage biopharmaceutical company focused on developing non-hallucinogenic psychedelic-derived neuroplastogens. The company is dedicated to creating scalable treatments for neuropsychiatric, metabolic, and addiction disorders, particularly AUD. Clearmind is listed on the Nasdaq under the ticker symbol CMND and operates under the SIC code 2834, which pertains to pharmaceutical preparations.
What the Filing Says
The recent filing states, "Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone." This indicates that the company has successfully enrolled patients for this critical phase of its clinical trial.
Impact
This development could significantly impact various stakeholders, including patients suffering from AUD, researchers involved in the trial, and investors interested in the pharmaceutical preparations sector. The trial is being conducted at prestigious clinical research sites, including Johns Hopkins University School of Medicine and Yale School of Medicine, which may enhance the credibility and visibility of the study.
What's Next
The filing does not specify what happens next, but it is expected that Clearmind will analyze the trial data to further understand CMND-100's safety, tolerability, and pharmacokinetic profile. This data will be crucial in supporting the advancement of the treatment candidate toward future development milestones.
Read Next
Kaltenbach acquires 534 shares in Mettler Toledo
Keller Gerry Acquires Shares in Mettler Toledo
CFO Shawn Vadala acquires 176 shares in Mettler Toledo
Eli Samaha discloses sale of 9.2 million Theravance shares
Davion Healthcare to Acquire Independence Care Network
Tompkins Financial updates on conference participation





